ASH 2022 | The benefits of bispecific antibodies over CAR-T cell therapy in lymphoma
Chan Yoon Cheah, MBBS, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, describes the potential benefits of bispecific antibodies over CAR-T cell therapy in lymphoma. While there is currently no randomized clinical trial data comparing the two, Dr Cheah highlights why he anticipates that bispecific antibodies will have dramatic uptake once approved, due to their off-the-shelf nature. However, Dr Cheah also notes a few limitations with the use of bispecifics, including the similarities in toxicity profiles, the time taken for step-up dosing of these agents, and that bispecifics must be dosed repeatedly rather than being a one-and-done treatment like CAR-T. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Beigene: Consultancy, Honoraria; TG Therapeutics: Consultancy, Honoraria; Eli Lilly and Company: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria, Research Funding; Gilead: Consultancy, Honoraria; Merck Sharp & Dohme: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Roche: Consultancy, Honoraria, Research Funding.
